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Summary
Background: Adriamycin (ADM) and ifosfamide (IFO) are the
two most active agents in the treatment of soft tissue sarcomas
(STS) with a clear dose-response relationship. We evaluated
the feasibility and toxicity of a high-dose IFO-plus-ADM
combination.
Patients and methods: Fourteen patients with advanced
disease and nine patients in adjuvant setting received IFO 12.5
g/m2 in 120-hour continuous infusion with Mesna uroprotec-
tion and ADM 20 mg/m2 on days 1-3 and G-CSF every three
weeks.
Results: Twenty-three patients received 89 chemotherapy
cycles (70 cycles at full dose). Seventeen patients received the
planned treatment, and nine patients required dose reductions.
We observed grade 3-4 neutropenia in 52 cycles (59%)/20
patients; grade 3-4 thrombocytopenia in 16 cycles (18%)/nine
patients; grade 3-4 anaemia in 24 cycles (27%)/ll patients.
Eight patients experienced febrile neutropenia and six patients
required blood transfusions.
Conclusions: While feasible, this regimen showed heavy
toxicity. Nevertheless, 74% of the patients were able to com-
plete the planned treatment. Adjustment of the schedule of
IFO continuous infusion to improve this combination is cur-
rently under investigation.
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Introduction
Only a few drugs have shown activity in the treatment of
soft tissue sarcomas (STS). Doxorubicin (ADM) has
yielded a response rate of 15% to 35%, with a proven
dose-response relationship.
Ifosfamide (IFO) has shown an 18%—20% response
rate as both first- and second-line treatment in meta-
static STS when administered at standard doses (5 g/m2),
and promising response rates ranging from 17% to 66% at
higher dose, with a proven dose-response relationship.
Trials testing full doses of an anthracycline in combi-
nation with maximal doses of IFO are not homogene-
ous: data concerning response are few and inconclusive,
although response rates of 50%-63% have been reported
[1-6]. The highest reported dose of IFO in combination
with an anthracycline without peripheral blood stem cell
support was 12.5 g/m2 and the two reports testing this
regimen showed different toxicity results [2, 6]. We de-
cided therefore to assess the feasibility and toxicity of a
regimen combining high-dose. IFO (12.5 g/m2) and
standard-dose ADM (60 mg/m2).
Patients and methods
From May 1995 through February 1997, 23 patients with Soft Tissue
Sarcoma (STS), 10 men and 13 women, aged 15 to 69 years (median age
45 years), entered the study. A total of 89 cycles of chemotherapy were
administered, 70 cycles at full dose and 19 cycles at reduced doses.
Fourteen patients had advanced disease and nine were treated in an
adjuvant setting. Only one of 23 patients was pretreated with anthracy-
cline; since relapse occurred more than six months after treatment
discontinuation, he has not been considered anthracycline-resistant.
Histologic subtypes were leiomyosarcoma (ten patients), alveolar
rhabdomyosarcoma in adults (three patients), liposarcoma (two pa-
tients), other STS (eight patients). All STS were high or intermediate
grade.
Sites of primary tumour in patients with advanced disease were as
following: the extremities (four patients), gluteal region (three patients),
gastro-intestinal/retroperitoneal (three patients), breast (two patients),
pelvis (one patient), mediastinum (one patient). Exclusion criteria
included ECOG performance status >2, age over 70 years, CNS
involvement or other health problems that might prevent full compli-
ance with the study. Informed consent was obtained from all patients.
IFO 12.5 g/m2 continuous-infusion over 120 hours with Mesna
uroprotection (175% IFO dose) and adriamycin 20 mg/m2 i.v. bolus
on days 1-3, plus 3000 ml of glucosate solution 5%, desametasone 8 mg
and granisetron 3 mg daily, were administered every three weeks.
Prophylactic G-CSF 5 mg/kg s.c. was given daily on days 7-14.
Four cycles of treatment in the adjuvant setting were planned, six
cycles for responding patients and four for patients with stable disease.
Toxicity was evaluated according to WHO criteria; a complete
blood cell count was performed twice a week.
In the presence of grade 4 thrombocytopenia, grade 3-4 febrile
neutropenia (T > 38 °C) requiring hospitalisation, grade 1 neutropenia
after treatment delay ^ 2 weeks or leucoencephalopaty, a 20% reduc-
tion of the total dose of IFO (except in one patient, who received a
dose reduction of 25% of both drugs) was performed for all subsequent
cycles.
Drop-out occurred if the same toxicity occurred despite dose
reduction or if > grade 1 haematological toxicity persisted after treat-
ment delay 3= 2 weeks or because of grade 3-4 neutropenia associated
with fever for over a week.
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Results
Overall toxicity
Twenty-three patients received 89 cycles of chemother-
apy, 70 of the cycles at full dose.
Seventeen patients (74%) completed the treatment as
planned. Interruption of the treatment program in the
remaining six patients was according to drop-out crite-
ria in three cases and because of patient refusal in three
cases. Overall, nine patients required dose reductions;
two of them had to discontinue treatment altogether
before completion.
Grade 3-4 haematological toxicity is reported in
Table 1.
Four patients required hospitalisation because of
febrile neutropenia (T > 38 °C > 48 hours); none of
them experienced infection or sepsis, haemorrhaged or
required platelet transfusion.
One patient developed acute leukoencephalopathy,
grade 3 mucositis occurred in three patients (13%)/five
cycles (6%). All patients experienced grade 2 alopecia.
No renal toxicity nor grade 3-4 nausea or vomiting
were reported.
Full-dose regimen toxicity
All 70 full-dose cycles, administered to 23 patients, were
evaluable for toxicity.
Grade 3-4 haematological toxicity is reported in
Table 2.
No cumulative neutropenia can be detected; 16 grade
3-4 episodes occurred during the first 23 cycles of treat-
ment.
Because of febrile neutropenia four patients required
hospitalisation. Three patients (14%) experienced grade 3
mucositis.
Table 1. Overall toxicity (89 cycles, 23 patients).
Toxicity
Neutropenia
Thrombocytopenia
Anemia
Neurotoxicity
Mucositis
Renal toxicity
Nausea vomiting
Grade 3
Cycles
n (%)
14(16)
12(13)
19(21)
_
5(6)
-
-
(WHO)
Patients
n (%)
5(22)
6(26)
7(30)
-
3(13)
-
—
Grade 4 (WHO)
Cycles
n (%)
38 (43)
4(4)
5(6)
1(1)
-
-
-
Patients
n (%)
15(65)
3(13)
4(17)
1(4)
-
-
-
Other events Cycles
n (%)
Patients
n (%)
Febrile neutropenia
Blood transfusions
13(15)
10(11)
8(35)
6(26)
Table 2. Toxicity: full-dose regimen schedule (70 cycles, 23 patients).
Toxicity
Neutropenia
Thrombocytopenia
Anemia
Neurotoxicity
Mucositis
Renal toxicity
Nausea vomiting
Grade 3
Cycles
« (%)
11(16)
9(13)
13(19)
-
5(7)
-
-
(WHO)
Patients
n (%)
5(22)
5(22)
7(30)
-
3(13)
-
-
Grade 4
Cycles
n (%)
30 (43)
3(4)
4(6)
1(1)
-
-
-
(WHO)
Patients
n (%)
15(65)
3(13)
3(13)
1(4)
-
-
-
Other events Cycles
n (%)
Patients
n (%)
Febrile neutropenia
Blood transfusions
11(16)
5(7)
7(30)
5(22)
Responses
All 14 patients with advanced disease were evaluable for
response. We observed two complete and five partial
responses with a 50% overall response rate (confidence
interval (CI): 23%-77%); six patients had stable disease
and one patient progressed.
With a median follow-up of nine months (range two
to 25+), the median survival has not yet been deter-
mined; the median time to progression was nine months
(range six to 15) in eight patients; six patients are still in
response (range 4+-9+).
Discussion
The main purpose of this study was to evaluate the
feasibility and toxicity of a poly-chemotherapy regimen
containing IFO 12.5 g/m2 and ADM 60 mg/m2 associ-
ated with G-CSF, every three weeks.
Of 23 patients in the group, 17 (74%) received the
planned treatment, while six had to discontinue treat-
ment before completion of the schedule. Moreover,
seven of 17 and two of six patients had dose reductions
during treatment.
Myelosuppression was the predominant toxicity ob-
served. Febrile neutropenia occurred in eight patients
(35%)/13 cycles (15%), four of them requiring hospi-
talisation. Nine patients (39%) experienced grade 3-4
thrombocytopenia in 16 cycles (18%), six of them requir-
ing blood transfusions. There were no deaths, sepsis or
bleeding complications. As for the 70 full-dose cycles,
febrile neutropenia occurred in 11 cycles (16%), whereby
four patients required hospitalisation and five received
blood transfusions.
In three cases the interruption of treatment before
completion was due to neutropenia, while in the remain-
ing three such interruptions were due to the patients'
refusal.
Overall, as a consequence of treatment toxicity, both
drugs were administered at 85% of the planned dose-
intensity:
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The data on the efficacy of the studied treatment are
inconclusive because of the heterogenicity of the popu-
lation and the limited number of patients with advanced
disease. Among the 14 patients evaluable, we obtained
two complete responses, five partial responses, and only
one disease progression.
Literature data on the toxicity of regimens containing
high-dose IFO and an anthracycline do not identify any
one less-myelotoxic combination, since different doses
of anthracycline and IFO have been used in the few
reported experiences [2-6]. Few studies have been re-
ported using a schedule similar to the one we tested.
A dose-finding study by the Italian Group for the
Study of Rare Tumours (IGSRT) on advanced adult
STS found a maximal tolerable dose of IFO 10.5 g/m2
in three days plus epirubicin 120 mg/m2 [1].
Reichardt reported grade 3-4 haematotoxicity in all
46 patients with advanced STS treated with a schedule
containing IFO 12.5 g/m2 and EpiADM 90 mg/m2 [2].
Nevertheless, in a dose-finding study on metastatic
breast cancer [6], authors recommended total IFO and
ADM doses equal to those used in our schedule after
five levels of IFO dose-escalation.
From these data it follows that future studies on the
treatment of STS should aim to reduce the haematolog-
ical toxic effects of the combination of h.d. IFO and full-
dose anthracycline to increase its feasibility.
The most interesting possibility for reducing the tox-
icity of our combination consists of a modification in the
administration schedule for IFO, using a prolonged out-
patient infusion of a daily low dose [7-9].
Out-patient 10-day continuous infusion of IFO 13
g/m2 [9] administered by portable pump showed a 30%
Grade 3-4 neutropenia; even lower myelosuppression
was registered in preliminary data by the IGSRT by a
further prolongation of the infusion, whereby IFO 1 g/m2
was administered daily over a 14-day period every three
weeks, without growth factor support [10].
Another interesting research approach would be to
combine with high-dose IFO the liposomal formulation
of ADM, which has show minimal myelosuppression in
the absence of growth factor support. However, only a
few preliminary data on liposomal doxorubicin activity
in STS are as yet available [11, 12] and we cannot assess
its role in the management of these tumours.
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